Nisa Investment Advisors
AVTX icon

Nisa Investment Advisors’s Avalo Therapeutics AVTX Stock Holding History

Nisa Investment Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$2K – 2376
2022
Q1 		$2K Hold
1
– – ﹤0.01% 2338
2021
Q4 		$3K Hold
1
– – ﹤0.01% 2109
2021
Q3 		$7 Hold
1
– – ﹤0.01% 2235
2021
Q2 		$10 Hold
1
– – ﹤0.01% 2224
2021
Q1 		$9 Hold
1
– – ﹤0.01% 2214
2020
Q4 		$8K Buy
+1
New +$6.95K ﹤0.01% 2234
2020
Q3 		– Hold
0
– – – 2232
2020
Q2 		– Hold
0
– – – 2033
2020
Q1 		– Hold
0
– – – 2038

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nisa Investment Advisors's AVTX Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 1 share — an estimated $2K sold.

Nisa Investment Advisors first reported a position in AVTX in Q4 2020 and held it in 6 quarters. The position peaked at $8K in Q4 2020. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • Nisa Investment Advisors reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 1 Avalo Therapeutics share in Q2 2022, an estimated $2K.
  • Nisa Investment Advisors first reported a position in Avalo Therapeutics in Q4 2020 and held it in 6 quarters.
  • Nisa Investment Advisors's Avalo Therapeutics position peaked at $8K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.